RMEA:F:F-Resmed Inc DRC (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 19.5

Change

+0.10 (+0.52)%

Market Cap

USD 27.99B

Volume

300.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-4.55 (-1.12%)

USD 141.14B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

USD 95.12B
ESL:F EssilorLuxottica Société ano..

+5.10 (+2.50%)

USD 94.21B
BOX:F Becton Dickinson and Company

+4.40 (+2.03%)

USD 62.42B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-4.00 (-3.60%)

USD 39.34B
HYB:F HOYA Corporation

+1.05 (+0.97%)

USD 38.54B
RME:F ResMed Inc

+0.40 (+0.20%)

USD 28.97B
CBHD:F Coloplast A/S

+1.35 (+1.23%)

USD 25.77B
CBH:F COLOPLAST SP.ADR 1/10 DK1

-0.20 (-1.87%)

USD 25.37B
TUO:F Terumo Corporation

+0.10 (+0.67%)

USD 23.10B

ETFs Containing RMEA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.81% 89% A- 85% B
Dividend Return 0.62% 27% F 10% F
Total Return 26.43% 81% B- 78% C+
Trailing 12 Months  
Capital Gain 9.55% 80% B- 64% D
Dividend Return 0.81% 28% F 6% D-
Total Return 10.36% 72% C 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.63% 44% F 42% F
Dividend Return -1.55% 41% F 38% F
Total Return 0.08% 10% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 6.20% 97% N/A 93% A
Risk Adjusted Return -25.03% 36% F 33% F
Market Capitalization 27.99B 93% A 94% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.